AVITA Medical (ASX:AVH), a regenerative medicine company with a technology platform designed to address unmet medical need in therapeutic skin restoration, has announced that its American Depositary Shares ('ADS') have been approved to list on the NASDAQ.
The company will trade under the ticker symbol 'RCEL' while its common stock will continue to trade uninterrupted on the Australian Stock Exchange 'AVH'.
“Our listing on Nasdaq is an exciting next step for AVITA Medical. It builds on our established ASX shareholder base and provides broader access to investors in the United States and worldwide,” said Dr Michael Perry, AVITA Medical’s CEO.
“Following the robust uptake and adoption of our RECELL System by US burn centers, we view the trading of our American Depositary Shares on the Nasdaq as a natural extension of our growth plan.”